Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI110158

Network Theory in Autoimmunity: IN VITRO SUPPRESSION OF SERUM ANTI-DNA ANTIBODY BINDING TO DNA BY ANTI-IDIOTYPIC ANTIBODY IN SYSTEMIC LUPUS ERYTHEMATOSUS

Nabih I. Abdou, Helen Wall, Herbert B. Lindsley, John F. Halsey, and Tsuneo Suzuki

Department of Medicine, Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, Kansas 66103

Department of Biochemistry, University of Kansas Medical Center, Kansas City, Kansas 66103

Department of Microbiology, University of Kansas Medical Center, Kansas City, Kansas 66103

Veterans Administration Hospital, Kansas City, Missouri 64128

Find articles by Abdou, N. in: PubMed | Google Scholar

Department of Medicine, Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, Kansas 66103

Department of Biochemistry, University of Kansas Medical Center, Kansas City, Kansas 66103

Department of Microbiology, University of Kansas Medical Center, Kansas City, Kansas 66103

Veterans Administration Hospital, Kansas City, Missouri 64128

Find articles by Wall, H. in: PubMed | Google Scholar

Department of Medicine, Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, Kansas 66103

Department of Biochemistry, University of Kansas Medical Center, Kansas City, Kansas 66103

Department of Microbiology, University of Kansas Medical Center, Kansas City, Kansas 66103

Veterans Administration Hospital, Kansas City, Missouri 64128

Find articles by Lindsley, H. in: PubMed | Google Scholar

Department of Medicine, Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, Kansas 66103

Department of Biochemistry, University of Kansas Medical Center, Kansas City, Kansas 66103

Department of Microbiology, University of Kansas Medical Center, Kansas City, Kansas 66103

Veterans Administration Hospital, Kansas City, Missouri 64128

Find articles by Halsey, J. in: PubMed | Google Scholar

Department of Medicine, Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, Kansas 66103

Department of Biochemistry, University of Kansas Medical Center, Kansas City, Kansas 66103

Department of Microbiology, University of Kansas Medical Center, Kansas City, Kansas 66103

Veterans Administration Hospital, Kansas City, Missouri 64128

Find articles by Suzuki, T. in: PubMed | Google Scholar

Published May 1, 1981 - More info

Published in Volume 67, Issue 5 on May 1, 1981
J Clin Invest. 1981;67(5):1297–1304. https://doi.org/10.1172/JCI110158.
© 1981 The American Society for Clinical Investigation
Published May 1, 1981 - Version history
View PDF
Abstract

Regulation of serum anti-DNA antibody in systemic lupus erythematosus (SLE) by an antiidiotypic antibody was evaluated. Various sera from SLE patients in active and inactive states of their disease, as well as sera from normal individuals, were first completely depleted of anti-DNA and of DNA by affinity chromatography. The suppressive capacity of equimolar concentrations of the various depleted sera (blocking sera) on target lupus sera were determined. The target sera were from lupus patients with known DNA-binding capacity. Blocking sera from inactive SLE suppressed the binding of autologous anti-DNA antibody to [3H]DNA (n = 19,P < 0.01). Blocking sera from active SLE (n = 19), as well as human serum albumin, did not suppress. Sera from normal donors who had no contact with lupus patients or with lupus sera did not suppress (n = 14, P > 0.5), whereas those from normal donors who had contact with lupus patients or sera did suppress the binding (n = 5,P < 0.02). The anti-anti-DNA antibody suppressive activity in the inactive lupus serum was shown to be localized within the F(ab′)2 portion of immunoglobulin (Ig)G and could not be removed upon adsorption by normal human gammaglobulin. Furthermore, immune complexes could be detected by a Clq binding assay when the inactive lupus blocking sera were incubated with the anti-DNA antibody containing target sera. The specificity of the suppressive serum factor was shown by its inability to block the binding of tetanus toxoid to antitetanus antibody and its ability to block the binding of DNA to F(ab′)2 fragments of active lupus IgG.

Regulation of serum anti-DNA antibody levels by anti-antibodies could induce and maintain disease remission in lupus patients and prevent disease expression in normals.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1297
page 1297
icon of scanned page 1298
page 1298
icon of scanned page 1299
page 1299
icon of scanned page 1300
page 1300
icon of scanned page 1301
page 1301
icon of scanned page 1302
page 1302
icon of scanned page 1303
page 1303
icon of scanned page 1304
page 1304
Version history
  • Version 1 (May 1, 1981): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts